Get started
JOHNSON DRNJOHNSON DRNJOHNSON DRN

JOHNSON DRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

JNJB34 trade ideas

Buy JNJ for Stable Gains Amid Earnings Optimism Next Week - Key Insights: Johnson & Johnson demonstrated robust earnings performance with an EPS of $2.77, surpassing consensus estimates and reinforcing its defensive stock status. Its diverse portfolio and consistent ability to execute in volatile markets make it a strong candidate for growth-oriented and stability-focused investors. With a positive sentiment surrounding large-cap equities, JNJ is likely to continue attracting capital. - Price Targets: Next week targets for LONG positions: T1=$166, T2=$170. Stop levels: S1=$157, S2=$155. - Recent Performance: JNJ outperformed expectations in its latest earnings report, showcasing profitability and resilience in the face of broader economic headwinds. The company delivered solid results while navigating inflationary pressures, confirming its strength as a defensive player in the healthcare marketplace. - Expert Analysis: Analysts remain optimistic about JNJ’s execution capabilities, citing its strategic investments in R&D and global footprint. The earnings beat is seen as a validation of management’s effectiveness in maximizing profitability through cost controls, alongside maintaining strong demand across pharmaceuticals, medical devices, and consumer health segments. - News Impact: Broader market optimism surrounding strong earnings across top- tier corporations (e.g., Abbott, Goldman Sachs) enhances JNJ’s prospects for an earnings-season rally. Sector-wide attention on healthcare innovation further bolsters JNJ’s defensive appeal amid global health concerns, while its pricing power shields it from inflationary impacts.
NYSE:JNJLong
by CrowdWisdomTrading
Johnson & Johnson Wave Analysis – 18 April 2025 - Johnson & Johnson rising inside weekly price range - Likely to test resistance level 165.60 Johnson & Johnson continues to rise in the primary upward impulse wave 3, which started earlier from the major support level 145.00 (lower border of the weekly sideways price range from 2023). The upward reversal from the support level 145.00 previously formed the weekly Japanese candlesticks reversal pattern Hammer Doaji – which reflected the strength of this price level. Johnson & Johnson can be expected to rise to the next resistance level 165.60, the upper border of the active sideways price range.
NYSE:JNJLong
by FxProGlobal
Johnson & Johnson Beats Q1 Estimates, Premarket Not Doing WellJohnson & Johnson (NYSE: NYSE:JNJ ) on Tuesday reported better-than-expected Q1 results and lifted its sales forecast for the full year. Johnson & Johnson (NYSE: NYSE:JNJ ), together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide, operating in two segments, Innovative Medicine and MedTech. Posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion. However, analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha. Price Action Shares of Johnson & Johnson (NYSE: NYSE:JNJ ) were up about 1% immediately following the report, but the uptick was shortlived as the stock is down -0.54% in premarket trading. They entered the day up about 7% since the start of the year. The company lifted its projected sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange." Since reporting a disappointing 2025 sales outlook in January, the company closed its nearly $15 billion acquisition of Intra-Cellular Therapies and announced plans to lift its U.S. investment to more than $55 billion over the next four years.23 Technical Outlook Shares of NYSE:JNJ closed Monday's session up 1.73% and despite the Q1 Earnings beat, the premarket session tells a different story as the asset is down 0.54% in Tuesday's session. The asset is trading within an enclosed rectangular formation with a perfectly formed support and resistant zones as indicated in the chart. A break above the the key moving averages could cement a bullish breakout that may resort to a break above the $169 resistant point. With the RSI at 45.35, NYSE:JNJ is well positioned for a bullish campaign once traders digest the earnings news.
NYSE:JNJLong
by DEXWireNews
Johnson & Johnson (JNJ) Shares Drop Over 7%Johnson & Johnson (JNJ) Shares Drop Over 7% As the chart shows, Johnson & Johnson (JNJ) shares declined by approximately 7.6%, reaching their lowest level since late February. This marked one of the worst performances in the stock market yesterday. Why Did JNJ Shares Fall? Two major bearish factors contributed to the decline: A Texas judge rejected Johnson & Johnson's third attempt to settle lawsuits related to allegations that its baby powder and other talc-based products harmed consumers. On Tuesday, Johnson & Johnson announced that its upcoming acquisition of Intra-Cellular Therapies is expected to dilute adjusted earnings per share by approximately $0.25 for the full year 2025. Investors appear to have reacted negatively to this outlook, despite the company’s expectation that the deal will generate around $700 million in additional sales. Technical Analysis of JNJ Stock Chart Price movements in 2025 have formed an ascending channel (marked in blue), with indicators highlighting how: → The channel’s boundaries have acted as support and resistance levels. → The channel’s median line has served as a “magnet” for price action, reflecting the balance between supply and demand. As JNJ's share price approaches the lower boundary (circled), just above the psychological support level at $150—previously a key level in February—traders have reasons to anticipate that the decline may slow down or even lead to a significant rebound from this support area. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:JNJ
by FXOpen
Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With tens of thousands of lawsuits alleging links to cancer, the company's strategy to manage this liability via bankruptcy has been repeatedly struck down by courts, most recently rejecting a $10 billion settlement proposal. This forces J&J to potentially face over 60,000 individual claims in court, introducing immense financial uncertainty and the prospect of staggering legal costs and damages. Compounding these concerns is mounting scrutiny over the company's historical and recent marketing practices. A federal judge recently imposed a $1.64 billion penalty against J&J's pharmaceutical arm for misleading marketing of HIV medications, citing a "deliberate and calculated scheme." This follows earlier multi-million dollar settlements related to alleged improper financial inducements paid to surgeons for orthopaedic implants by its DePuy subsidiary, and tax disputes in India over questionable "professional sponsorship" expenses tied to similar activities. These incidents depict recurring legal and ethical entanglements with significant financial penalties and reputational harm. Taken together, the unresolved talc litigation, substantial financial penalties from marketing violations, and persistent questions regarding ethical conduct create considerable headwinds for Johnson & Johnson. The cumulative impact of ongoing legal battles, potential future liabilities, and damage to its corporate image threatens to drain resources, divert management focus from core operations, and erode investor confidence. These converging factors present tangible risks that could exert significant downward pressure on the company's stock price moving forward.
NYSE:JNJShort
by UDIS_View
Johnson&Johnson: Rejected AgainJohnson&Johnson has now been rejected at the $168.75 resistance level for the second time, pulling back more noticeably in response. However, in our primary scenario, we still expect an imminent breakout above this level, which should allow the turquoise wave X to establish its high well above it. Afterward, the turquoise wave Y should drive the stock sharply lower again, as we anticipate the low of the larger green wave in the corresponding long Target Zone between $138.78 and $125.75. That said, reaching this Zone is not a certainty. There remains a 35% chance that the low of the green wave alt. is already settled. Under this alternative scenario, the stock would break through $168.75 without resistance and continue its impulsive move higher.
NYSE:JNJ
by MarketIntel
$JNJ bull just wont stopJohnson & Johnson: A Healthcare Giant Did you know that Johnson & Johnson has been a leading player in the healthcare industry for over 135 years? Founded in 1887 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr., the company has grown to become a global powerhouse with a diverse portfolio of products. **Innovative Medicine and MedTech Segments** Johnson & Johnson operates through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on research and development of treatments for various diseases, including: * Immunology * Infectious diseases * Neuroscience * Oncology * Cardiovascular and metabolism * Pulmonary hypertension The MedTech segment, on the other hand, includes a range of products used in: * Interventional solutions * Orthopaedics * Surgery * Vision **A Legacy of Innovation** With a rich history and a commitment to innovation, Johnson & Johnson continues to shape the healthcare landscape. From its humble beginnings to its current status as a global leader, the company remains dedicated to improving lives through its products and services. Would you like to know more about Johnson & Johnson's history or its current products and initiatives? Let me know in the comments!
NYSE:JNJLong
by ImmaculateTony
JNJ - Potential Sell Opportunity at Resistance LevelNYSE:JNJ has reached a significant resistance zone, marked by prior price rejections and strong selling pressure. This area has historically acted as a key supply zone, indicating the potential for a pullback if sellers regain control. The current market structure suggests that if the price confirms a rejection from this resistance zone, there is a high likelihood of a downward move. I anticipate that if rejection occurs, the market may head lower toward the 155.00 level, which represents a logical target within the current market structure. This setup reflects the potential for a retracement after an impulsive move, supported by the confluence of previous price behavior and the current structure. If you agree with this analysis or have additional insights, feel free to share your thoughts in the comments!
NYSE:JNJShort
by DanieIM
3
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
JNJ – Potential Buy Opportunity at Support LevelThe JNJ stock price is currently approaching a key demand zone. If the price finds support and bullish confirmation signals appear, such as bullish candlestick patterns or long lower wicks, we could see a potential rebound. The first target for this move would be around the $153.03 level. This setup offers an opportunity for a long position if the demand zone holds. Traders should monitor for additional confirmation before entering. Do you agree with this analysis, or do you have alternative views on this setup? Share your thoughts in the comments!
NYSE:JNJLong
by DanieIM
Johnson & Johnson (JNJ) Posted Q4 Earnings BeatJohnson & Johnson (JNJ) recently reported its fourth-quarter earnings, showcasing a performance that beat analyst expectations with an EPS of $2.04 against a forecast of $1.99 and sales of $22.52 billion, in line with the anticipated $22.45 billion. Despite this positive financial news, J&J's stock took a tumble, closing down 1.9% at $145.27 after issuing guidance for 2025 that fell short of Wall Street's expectations. The company projected sales between $89.2 billion and $90 billion, below the Street's estimate of $91.04 billion, and an adjusted profit per share from $10.50 to $10.70, bracketing the consensus of $10.55. A Mixed Bag Innovative Medicines Shine: J&J's innovative medicines segment saw a 4.4% growth, contributing significantly to the quarter's performance. Standout performers included Spravato, which grew by 44% year-over-year, and cancer drugs like Darzalex and Erleada, alongside blood thinners which increased by nearly 30%. However, the looming patent expiration for Stelara, a major immunology drug, casts a shadow over future earnings from this segment. MedTech Segment Under Pressure: On the downside, medical device sales underperformed, coming in at $8.19 billion against expectations of $8.22 billion. This segment faces challenges, particularly in China, but there's optimism with new investments and product launches like the Ottava surgical robot, which could challenge Intuitive Surgical's market dominance in the future. External Headwinds: J&J is dealing with several external pressures including foreign exchange issues, which have impacted their sales guidance for 2025. Additionally, potential generic competition and ongoing litigation related to talc products continue to be significant headwinds. Technical Analysis Premarket Recovery: Despite the post-earnings drop, NYSE:JNJ shares showed a 0.60% uptick in premarket trading on Thursday, suggesting some investor confidence returning. RSI and Patterns: The Relative Strength Index (RSI) at 50.48 indicates a moderate condition, neither overbought nor oversold, providing a balanced outlook. The stock's monthly chart shows a falling wedge pattern, typically a bullish indicator if broken upwards. A breakout above this pattern could signal a bullish campaign for $JNJ. However, there's a risk of further decline if the support at $145 breaks, potentially leading to a dip towards the one-month low of $140. Moving Averages: NYSE:JNJ currently trades below its 50-day moving average, suggesting short-term bearish sentiment, but a recovery above this average could signal the beginning of a recovery trend. Forward-Looking Perspective Despite the immediate challenges, analysts like Edward Jones' John Boylan see J&J's guidance as conservative but achievable, particularly with the company's strategic focus on new product development and pipeline expansion in both pharmaceuticals and medical technology. The emphasis on cancer drugs, robotics, and cardiovascular products is seen as a pathway to long-term growth and margin expansion. Conclusion Johnson & Johnson, while grappling with short-term headwinds, holds a portfolio of products with strong growth potential. The technical setup suggests that if JNJ can maintain or surpass current support levels, there's room for optimism. Investors might see this as an opportunity to buy into a dip, given the company's history of innovation and resilience. However, caution is advised due to the external factors and regulatory challenges ahead. The broader narrative for J&J seems to hinge on its ability to innovate and adapt in a rapidly changing healthcare market environment.
NYSE:JNJLong
by DEXWireNews
Johnson & Johnson: Awaiting ResultsJohnson & Johnson (NYSE: JNJ), one of the global giants in the pharmaceutical, medical device and consumer sectors, is in the spotlight as it prepares to release its fourth-quarter 2024 results. Analysts and the market expect the results to reflect a combination of macroeconomic challenges and strategic opportunities that will define its performance in 2025. Expected Q4 2024 results 1. Pharmaceuticals: The pharmaceutical business remains the key revenue driver for J&J, driven by drugs such as Stelara (treatment for immune diseases) and Darzalex (multiple myeloma). However, the recent loss of exclusivity for some products could affect revenues, especially in key markets such as the United States and Europe. o Expected revenues: Moderate growth of 3-5% year-on-year is projected in the pharmaceutical segment. 2. Medical devices: The post-pandemic recovery has favored this segment, with an increase in surgical procedures and advanced therapies. However, supply chain issues and high material costs could limit gains. 3. Consumer products: The consumer division, now under the Kenvue brand, has experienced stable growth thanks to products such as Tylenol and Neutrogena. However, competition in this market remains intense, which could limit profit margins. Technical analysis with WACD The company is currently in a price correction that began in September 2024 and has moved since December last year in a range between $150 and $142 a share. Currently there have been bearish signals in the WACD indicator in its WVAP signal that show us that it can correct its price again in that range. On the other hand the smoothed triple mean seems to be extending its move from the recent lows, indicating that this signal could be short-lived and could send the price subsequently towards the high end of the range if the expected results are as indicated. Outlook for 2025 1. Pharmaceutical innovation: Johnson & Johnson has strengthened its focus on research and development, with a robust pipeline that includes oncology treatments and advanced gene therapies. Expected new drug approvals could be a key catalyst for long-term growth. 2. Legal Challenges: Litigation related to talc and other consumer products continues to be a source of uncertainty. While J&J has established a compensation fund, legal costs could affect its results in 2025. 3. Digital transformation and sustainability: The company is investing in digital technologies to improve operational efficiency and in sustainability initiatives that align its business model with market and regulatory expectations. Conclusion Johnson & Johnson faces a mixed picture in the near term, with challenges in some key segments and growth opportunities in others. Fourth quarter 2024 results will be crucial in gauging its ability to overcome current pressures and capitalize on its innovation strategy in 2025. With a focus on diversification and innovation, J&J remains a benchmark in the healthcare sector, but its success will depend on how it manages legal and macroeconomic risks in the coming years. Ion Jauregui - ActivTrades Analyst ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acing on the information provided does so at their own risk.
NYSE:JNJ
by ActivTrades
Johnson & Johnson Sees Possible Bullish Chart Ahead of EarningsJohnson & Johnson NYSE:JNJ will report Q4 numbers next Wednesday (Jan. 22) at a time when the medical company’s stock has been under the weather, falling back some 14% since early September even as the S&P 500 gained about 7%. What does JNJ’s technical and fundamental analysis say could happen from here? Let’s look: Johnson & Johnson’s Fundamental Analysis The Street is looking for JNJ to report $2.04 in adjusted Q4 earnings per share on $22.5 billion in revenue. That would reflect about 4.9% in sales growth year over year, but also show a 10.9% drop in adjusted EPS from the $2.29 that Johnson & Johnson saw in Q4 2023. Of the 15 sell-side analysts that I know of who follow JNJ, all 15 have revised their Q4 estimates lower since the quarter began. But the company also had some interesting news this week. On Monday, Johnson & Johnson announced the acquisition of biopharma firm Intra-Cellular Therapies NASDAQ:ITCI for $14.6 billion, or a cool $132 per share in an all-cash deal. The idea is to strengthen JNJ's neurosciences portfolio. At least the firm recognizes that either you grow organically or you “buy” growth. Doing nothing isn’t usually a good solution. Intra-Cellular Therapies brings with it a drug called Caplyta, an oral treatment for schizophrenia. Caplyta generated more than $175 million in sales for Q3, up from less than $126 million in the same quarter one year earlier. ITCI isn’t a cash-flow beast by any stretch, but the firm has no debt on the balance sheet. So, JNJ is buying potential, not somebody else's financial problems. In fact, Intra-Cellular had more than $1 billion in cash on hand as of Sept. 30. Additionally, ITCI has a promising candidate (ITI-128) currently in Phase 2 testing as a potential therapy for generalized anxiety disorder and Alzheimer's-related psychosis. Johnson & Johnson’s Technical Analysis Now let’s look at Johnson & Johnson’s chart going back six months: Readers will see that the stock has been very responsive since the summer to traditional technical analysis. JNJ developed a so-called “rising wedge” from July into September, as denoted by green shading at the chart’s left. That’s historically a pattern of bearish reversal. The rising wedge ultimately culminated in a “double-top” pattern of bearish reversal, which apexed in both early and mid-September (marked with two red boxes in the above chart). Lo and behold, the stock became mired in a downward trend after that. However, JNJ has recently developed a “falling wedge,” denoted by the red box at right. That’s usually a pattern of bullish reversal. Readers will also note that Johnson & Johnson’s most recent low occurred right around the time the stock suffered a "death cross.” That’s when a stock’s 50-day Simple Moving Average (Or “SMA,” marked with a blue line) crosses below its 200-day SMA (the red line). This often causes a negative algorithmic reaction that leads to further bearish behavior. I don't know when (or if) the falling-wedge pattern’s bullishness will come to fruition, but I do know that Johnson & Johnson could definitely use a positive catalyst. Next week’s Q4 earnings could provide that, as CEO Joaquin Duato will get a chance to talk up the Intra-Cellular Therapies acquisition during the company’s earnings call. I also know that JNJ is pressuring its 21-day Exponential Moving Average (or “EMA,” marked with a green line) from below. That could put swing traders on alert. Such activity could put the 50-day SMA in play if there’s a rebound. That could serve as the stock’s upside pivot point. As for other technical indicators, Johnson & Johnson’s Relative Strength Index (the gray line at the chart’s top) looks like it’s improving. However, the stock’s daily Moving Average Convergence Divergence indicator (or “MACD”) shows that both the 12-day EMA (the black line at the chart’s bottom) and the 26-day EMA (the gold line) remain mired in negative territory. Still, the histogram of JNJ’s 9-day EMA (the blue bars at bottom) has recently found its way into positive territory. (Moomoo Technologies Inc. Markets Commentator Stephen “Sarge” Guilfoyle” had no position in JNJ at the time of writing this column.) This article discusses technical analysis, other approaches, including fundamental analysis, may offer very different views. The examples provided are for illustrative purposes only and are not intended to be reflective of the results you can expect to achieve. Specific security charts used are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. This content is also not a research report and is not intended to serve as the basis for any investment decision. The information contained in this article does not purport to be a complete description of the securities, markets, or developments referred to in this material. Moomoo and its affiliates make no representation or warranty as to the article's adequacy, completeness, accuracy or timeliness for any particular purpose of the above content. Furthermore, there is no guarantee that any statements, estimates, price targets, opinions or forecasts provided herein will prove to be correct. Moomoo is a financial information and trading app offered by Moomoo Technologies Inc. In the U.S., investment products and services on Moomoo are offered by Moomoo Financial Inc., Member FINRA/SIPC. TradingView is an independent third party not affiliated with Moomoo Financial Inc., Moomoo Technologies Inc., or its affiliates. Moomoo Financial Inc. and its affiliates do not endorse, represent or warrant the completeness and accuracy of the data and information available on the TradingView platform and are not responsible for any services provided by the third-party platform.
NYSE:JNJ
by moomoo
1